These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 16922620

  • 1. Hodgkin's lymphoma: molecular targets and novel treatment strategies.
    Yazbeck V, Georgakis GV, Wedgwood A, Younes A.
    Future Oncol; 2006 Aug; 2(4):533-51. PubMed ID: 16922620
    [Abstract] [Full Text] [Related]

  • 2. Hodgkin's disease: classification and differential diagnosis.
    Harris NL.
    Mod Pathol; 1999 Feb; 12(2):159-75. PubMed ID: 10071341
    [Abstract] [Full Text] [Related]

  • 3. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment.
    Steidl C, Connors JM, Gascoyne RD.
    J Clin Oncol; 2011 May 10; 29(14):1812-26. PubMed ID: 21483001
    [Abstract] [Full Text] [Related]

  • 4. Molecular pathogenesis of Hodgkin's lymphoma.
    Re D, Küppers R, Diehl V.
    J Clin Oncol; 2005 Sep 10; 23(26):6379-86. PubMed ID: 16155023
    [Abstract] [Full Text] [Related]

  • 5. Nodular lymphocyte predominant Hodgkin's lymphoma.
    Siddiqui N, Al-Diab AI.
    Saudi Med J; 2005 Feb 10; 26(2):241-5. PubMed ID: 15770298
    [Abstract] [Full Text] [Related]

  • 6. Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.
    Carlo-Stella C, Santoro A.
    Biomark Med; 2015 Feb 10; 9(8):807-17. PubMed ID: 26223461
    [Abstract] [Full Text] [Related]

  • 7. [Hodgkin's disease: biology can help the physician towards new prognostic factors and new therapeutic approaches].
    Rubio MT, Ghesquières H, Blay JY, Salles G.
    Bull Cancer; 2001 Nov 10; 88(11):1081-90. PubMed ID: 11741802
    [Abstract] [Full Text] [Related]

  • 8. [WHO classification of Hodgkin's lymphoma and its molecular pathological relevance].
    Hansmann ML, Willenbrock K.
    Pathologe; 2002 May 10; 23(3):207-18. PubMed ID: 12089788
    [Abstract] [Full Text] [Related]

  • 9. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
    Shimabukuro-Vornhagen A, Haverkamp H, Engert A, Balleisen L, Majunke P, Heil G, Eich HT, Stein H, Diehl V, Josting A.
    J Clin Oncol; 2005 Aug 20; 23(24):5739-45. PubMed ID: 16009944
    [Abstract] [Full Text] [Related]

  • 10. Hodgkin's disease, lymphocyte predominance type, nodular--further evidence for a B cell derivation. L & H variants of Reed-Sternberg cells express L26, a pan B cell marker.
    Pinkus GS, Said JW.
    Am J Pathol; 1988 Nov 20; 133(2):211-7. PubMed ID: 3263805
    [Abstract] [Full Text] [Related]

  • 11. [Pathology of Hodgkin's lymphoma].
    Hansmann ML, Willenbrock K.
    Verh Dtsch Ges Pathol; 2003 Nov 20; 87():53-7. PubMed ID: 16888894
    [Abstract] [Full Text] [Related]

  • 12. Hodgkin's lymphomas: classification, diagnosis, and grading.
    Harris NL.
    Semin Hematol; 1999 Jul 20; 36(3):220-32. PubMed ID: 10462322
    [Abstract] [Full Text] [Related]

  • 13. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma.
    Bräuninger A, Hansmann ML, Strickler JG, Dummer R, Burg G, Rajewsky K, Küppers R.
    N Engl J Med; 1999 Apr 22; 340(16):1239-47. PubMed ID: 10210707
    [Abstract] [Full Text] [Related]

  • 14. Histopathology of Hodgkin's lymphoma.
    Eberle FC, Mani H, Jaffe ES.
    Cancer J; 2009 Apr 22; 15(2):129-37. PubMed ID: 19390308
    [Abstract] [Full Text] [Related]

  • 15. Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.
    Carbone A, Gloghini A, Castagna L, Santoro A, Carlo-Stella C.
    J Pathol; 2015 Sep 22; 237(1):4-13. PubMed ID: 25953622
    [Abstract] [Full Text] [Related]

  • 16. Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization.
    Hartmann S, Martin-Subero JI, Gesk S, Hüsken J, Giefing M, Nagel I, Riemke J, Chott A, Klapper W, Parrens M, Merlio JP, Küppers R, Bräuninger A, Siebert R, Hansmann ML.
    Haematologica; 2008 Sep 22; 93(9):1318-26. PubMed ID: 18641027
    [Abstract] [Full Text] [Related]

  • 17. Nodular lymphocyte predominant Hodgkin's disease and anaplastic large-cell (CD30+) lymphoma: distinct entities or nonspecific patterns?
    Menestrina F, Chilosi M, Scarpa A.
    Semin Diagn Pathol; 1995 Aug 22; 12(3):256-69. PubMed ID: 8545592
    [Abstract] [Full Text] [Related]

  • 18. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma.
    van den Berg A, Visser L, Poppema S.
    Am J Pathol; 1999 Jun 22; 154(6):1685-91. PubMed ID: 10362793
    [Abstract] [Full Text] [Related]

  • 19. Nodular lymphocyte predominant Hodgkin lymphoma.
    Lee AI, LaCasce AS.
    Oncologist; 2009 Jul 22; 14(7):739-51. PubMed ID: 19605845
    [Abstract] [Full Text] [Related]

  • 20. Targeting macrophages in classical Hodgkin's lymphoma may seem rational, but is it safe?
    Dasanu CA.
    J Oncol Pharm Pract; 2012 Mar 22; 18(1):104-8. PubMed ID: 21248172
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.